Mitochondria-targeted aromatic-cationic tetrapeptide (Szeto-Schiller class)

SS-31

INN: Elamipretide CAS: 736992-21-5 MW: 639.79 g/mol Formula: C₃₂H₄₉N₉O₅

Key Takeaways

FDA accelerated approval (Forzinity, 19 September 2025) for Barth syndrome ≥30 kg is the first-ever marketing authorization for a mitochondria-targeted therapeutic; the approval rests on a 12-patient crossover trial that missed its randomized-phase primary endpoints, an open-label extension, and a natural-history comparator, with knee-extensor strength added as intermediate endpoint at resubmission. ⚠️🔴
Across the broader clinical programme (EMBRACE-STEMI, PROGRESS-HF, MMPOWER-3, ReCLAIM-2, LHON SPILH-201, the randomized phase of TAZPOWER), pre-specified primary endpoints were not met; post-hoc subgroup and open-label-extension analyses generated the principal regulatory and clinical narrative.
For the longevity / general-mitochondrial use case the optimization audience cares about, there is no controlled human evidence — Science Score 8 / Tier D — and the mechanistic literature remains heavily Szeto-laboratory dependent. 🔴
WADA: not named on the 2026 List, but off-label use defaults to S0 (Non-Approved Substances), banned at all times; BSCG explicitly names “SS-31” in its 2026 prohibited-substance guidance.
Community Score 56 / Tier C: SS-31 is the headline mitochondrial peptide of 2025–2026 in research-chemical channels, codified by the SS-31 + MOTS-c stack and Vigorous Steve / Jay Campbell / Peter Attia coverage; dose is split three ways (1–5 mg / 10–20 mg / 30–60 mg) with no community consensus, and fatigue is reported by a non-trivial minority as a paradoxical AE.

1. Identity

Field	Value	Source
INN	Elamipretide	[Academic secondary source — WHO INN list; FDA label NDA 215244]
Prior research codes	SS-31 (Szeto-Schiller peptide 31); MTP-131	[Peer-reviewed — Zhao 2004 J Biol Chem PMID 15184369]
Prior development brand	Bendavia (cardiac reperfusion programme)	[Peer-reviewed — Gibson 2016 Eur Heart J PMID 26586786]
Approved brand (US)	Forzinity™ (elamipretide hydrochloride) injection	[Regulatory — FDA Forzinity label 2025-09-19, NDA 215244]
CAS	736992-21-5 (free base); HCl salt is the approved drug substance	[Academic secondary source — PubChem CID 11764719 / 137528200]
Molecular formula	C₃₂H₄₉N₉O₅ (free base)	[Academic secondary source — PubChem CID 11764719]
Molecular weight	639.79 g/mol (free base)	[Academic secondary source — PubChem CID 11764719]
Sequence	H-D-Arg-Dmt-Lys-Phe-NH₂ (C-terminal amidation; Dmt = 2′,6′-dimethyl-L-tyrosine)	[Peer-reviewed — Birk 2013 JASN PMID 23813215]
Chemical class	Mitochondria-targeted aromatic-cationic tetrapeptide (Szeto-Schiller class)	[Peer-reviewed — Mitchell 2020 JBC PMID 32209654]
Originators	Hazel H. Szeto (Weill Cornell) and Peter W. Schiller (Clinical Research Institute of Montreal), ca. 2003–2004	[Peer-reviewed — Zhao 2004 J Biol Chem PMID 15184369] 🔴
Current sponsor	Stealth BioTherapeutics Inc. (Needham, MA); private since August 2022 (Morningside Ventures acquisition)	[Industry CSR — Stealth/Morningside Aug 2022 deal] ⚠️
Approved route	Subcutaneous injection (40 mg once daily; 280 mg / 3.5 mL vial = 80 mg/mL)	[Regulatory — FDA Forzinity label §2.1, §3]
Investigated routes	IV infusion (EMBRACE-STEMI, MMPOWER-1, PREVIEW, atherosclerotic renal artery stenosis); topical ophthalmic 1% solution (LHON SPILH-201)	[Clinical trial registry — NCT01572909, NCT02693119]
Plasma half-life (SC, healthy adults)	Terminal t½ ≈ 4 h; T_max ≈ 1–2 h; dose-proportional PK	[Regulatory — FDA Forzinity label §12.3]
Hepatic metabolism	None observed in vitro; not a CYP inhibitor/inducer at clinical exposure; two minor renal-cleared metabolites M1/M2	[Regulatory — FDA Forzinity label §12.3, §7]
First US approval	2025-09-19 (accelerated approval, Barth syndrome in patients ≥30 kg)	[Regulatory — FDA press release 2025-09-19]
Successor in development	SBT-272 / bevemipretide (related cardiolipin-binder, Phase 1, broader CNS penetration); SBT-255 preclinical	[Industry CSR — Stealth pipeline 2026] ⚠️

2. History and Development

The compound originated in the Szeto-Schiller laboratory collaboration between Weill Cornell Medical College and the Clinical Research Institute of Montreal in the early 2000s. The lead publication describing the “SS” series of cell-permeable, mitochondrially-targeted aromatic-cationic peptides was Zhao et al., Journal of Biological Chemistry, 2004 [Peer-reviewed — PMID 15184369] 🔴. The “31” denotes the compound’s position in the iterative medicinal-chemistry series; the design exploits an alternating aromatic / basic D-amino-acid motif that concentrates the peptide >1,000-fold inside mitochondria independently of mitochondrial membrane potential.

The molecule was licensed from Cornell to Stealth Peptides (founded ca. 2007), later renamed Stealth BioTherapeutics. The first major clinical pivot was the cardiac ischaemia-reperfusion programme under the brand Bendavia, culminating in the Phase 2a EMBRACE-STEMI trial (NCT01572909; Gibson et al., Eur Heart J 2016, PMID 26586786) ⚠️, which failed its primary efficacy endpoint (no reduction in CK-MB AUC₀–₇₂ infarct size) and effectively ended the cardiac-reperfusion development arc.

Stealth subsequently re-positioned the asset toward (a) primary mitochondrial myopathy (PMM) — MMPOWER, MMPOWER-2, MMPOWER-3; (b) Barth syndrome — TAZPOWER (crossover + open-label extension); (c) heart failure — PROGRESS-HF (HFrEF) and RESTORE-HF (HFpEF); (d) ophthalmology — ReCLAIM, ReCLAIM-2, topical SPILH-201 LHON, and the ongoing Phase 3 ReNEW in dry AMD (NCT06373731).

Stealth listed on Nasdaq (MITO) in 2019, suffered share-price collapse after the MMPOWER-3 readout, and was taken private in August 2022 via acquisition by Morningside Ventures [Industry CSR — Stealth/Morningside 2022] ⚠️.

The Barth syndrome NDA was first submitted August 2021, refused, then resubmitted 29 January 2024 and accepted April 2024. The FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) met 10 October 2024 and voted 10-6 that elamipretide was effective for Barth syndrome [Regulatory — CRDAC docket FDA-2024-N-3939]. After two PDUFA extensions and a Complete Response Letter (CRL) issued May 2025, Stealth and FDA agreed on an accelerated-approval pathway. Accelerated approval was granted 19 September 2025 for patients ≥30 kg with the intermediate clinical endpoint of knee-extensor muscle strength [Regulatory — FDA approval 2025-09-19]. A confirmatory trial is required to maintain approval.

A successor compound, bevemipretide (SBT-272), a related small-molecule cardiolipin-binder with broader CNS penetration, is in Phase 1 with preclinical activity reported in α-synucleinopathy, ALS, FTD, Huntington’s, and ischaemic-stroke models [Industry CSR — Stealth 2026] ⚠️.

3. Mechanism of Action

3.1 Demonstrated human mechanism

The FDA-approved Forzinity label states the mechanism as “elamipretide is a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function” [Regulatory — FDA Forzinity label §12.1]. No specific molecular receptor or enzymatic target has been identified in humans; the mechanism is described as biophysical (lipid-bilayer interaction) rather than receptor-mediated.

In the TAZPOWER open-label extension, plasma monolysocardiolipin / cardiolipin (MLCL/CL) ratios — a biochemical hallmark of Barth-syndrome tafazzin dysfunction — were measured as biomarker secondaries. The MLCL/CL ratio is not directly modified by elamipretide in a manner FDA has formally accepted as a surrogate (Thompson 2024 Genet Med) ⚠️.

3.2 Proposed / preclinical mechanism

The dominant mechanistic model — almost entirely Szeto-laboratory–derived 🔴 — runs as follows:

Selective targeting. The alternating aromatic / cationic D-amino-acid sequence allows passive membrane diffusion and >1,000-fold concentration in the matrix-facing leaflet of the inner mitochondrial membrane (IMM), driven primarily by electrostatic attraction to the anionic phospholipid cardiolipin [Zhao 2004; Birk 2013 JASN] 🔴.
Cardiolipin binding. A fluorescent polarity-sensitive SS-31 analogue binds cardiolipin with high affinity (Birk 2013 JASN) 🔴. Independent biophysical replication: Mitchell, Alder et al., J Biol Chem 2020 (University of Connecticut, with H. Szeto as co-author) confirmed that SS-31 partitions into anionic-lipid bilayers proportional to surface charge density and modulates membrane electrostatics rather than acting as a classical molecular antioxidant [Mitchell 2020 PMID 32209654]. The Alder lab is the principal non-Szeto site of mechanistic confirmation; co-authorship with Szeto qualifies the independence claim.
Functional consequences (preclinical). Stabilisation of respiratory super-complex assembly, improved electron-transport-chain coupling, reduced electron leak and consequently reduced mitochondrial ROS, restored ATP synthesis, attenuated cytochrome c peroxidase activity on the cardiolipin/cyt-c complex, suppressed mitochondrial permeability-transition-pore opening, and preserved cristae architecture under ischaemic stress [Szeto 2014 Br J Pharmacol; Birk 2014 Br J Pharmacol] 🔴.
Aged-tissue and disease models. Rapid restoration of skeletal muscle fatigue resistance in aged mice (Siegel 2013 Aging Cell PMID 23802411) 🔴; partial independent replication in C57BL/6J aged mice (2025 Aging Cell PMC12151887).

3.3 Mechanistic-narrative evolution

The framing has shifted between 2004 and 2020 from “cell-permeable peptide antioxidant” (free-radical scavenger model) to “cardiolipin chaperone / electrostatic membrane modulator” (Mitchell 2020). The 2020 Mitchell/Alder paper explicitly states that SS-31 does not act as a stoichiometric ROS scavenger; ROS reduction is downstream of cardiolipin stabilisation. This is an unusual case of a sponsor accepting reframing of its lead compound’s mechanism mid-development. See §7.5.

4. Regulatory Status

4.1 Drug-regulatory status

United States — FDA. Approved 2025-09-19 under accelerated approval as FORZINITY™ (elamipretide hydrochloride) injection to improve muscle strength in adult and paediatric patients with Barth syndrome weighing ≥30 kg [Regulatory — FDA approval letter NDA 215244]. Intermediate clinical endpoint: improvement in knee-extensor muscle strength; continued approval contingent on confirmatory trial [Regulatory — Forzinity label §1, §14]. Designations held: Orphan Drug Designation (Barth syndrome, 2018; PMM, 2017), Fast Track (2017), Rare Pediatric Disease Designation (2020), Priority Review, Rare Pediatric Disease voucher granted at approval [Industry CSR — Stealth releases 2017–2025] ⚠️. AdCom: CRDAC voted 10-6 in favour of efficacy on 10 October 2024 [Regulatory — Docket FDA-2024-N-3939]. CRL history: first-round CRL May 2025; resolved via accelerated-approval resubmission August 2025 [Regulatory — FDA CRL 2025-05] ⚠️. Other indications: no FDA approval. Phase 3 NuPOWER (PMM, nDNA-restricted) fully enrolled; Phase 3 ReNEW (NCT06373731) for dry AMD in progress.

503A / 503B compounding. Elamipretide is not listed on the FDA 503A bulks list as of 2026-05-15. June 2026 and July 2026 PCAC dockets address other peptides (DSIP, Semax, Epitalon); no PCAC review of elamipretide has been scheduled [Regulatory — FDA dockets 2025-N-6895, 2026-N-2979]. Because elamipretide is now an FDA-approved drug product (Forzinity), it is generally compoundable under §503A only as a copy of the approved product subject to the FD&C Act §503A(b)(1)(D) “essentially a copy” restriction, except in patient-specific shortage circumstances. Bulk-substance compounding outside the approved indication falls outside the established pathways for compounding pharmacies and outsourcing facilities.

European Union — EMA. Not approved. No EPAR. Orphan designation EU/3/21/2430, granted 20 May 2021, for Barth syndrome [Regulatory — EMA orphan designation]. No PMM, AMD, or other orphan designation identified.

United Kingdom — MHRA, Canada — Health Canada, Japan — PMDA, China — NMPA, South Korea — MFDS, Russia — GRLS: No marketing authorisation identified in any jurisdiction as of 2026-05-15. Stealth has publicly stated it is pursuing ex-US partnerships post-FDA approval [Industry CSR — Stealth 2025-09-19] ⚠️.

TGA scheduling (Australia). Elamipretide is not listed by name in the current Poisons Standard (SUSMP, February 2026 instrument) [Regulatory — Therapeutic Goods (Poisons Standard—February 2026) Instrument 2026]. As an unapproved prescription-strength injectable peptide, it functionally defaults to Schedule 4 (prescription-only) treatment under TGA Section 19 unapproved-goods access (Special Access Scheme Category A/B, Authorised Prescriber, or clinical trial) for any therapeutic use in Australia. Personal importation is restricted; no over-the-counter status exists.

WHO Essential Medicines List: Not listed (2023 update).

4.2 Anti-doping status

WADA Prohibited List 2026 (in force 1 January 2026): Elamipretide is not named explicitly. It does not fit cleanly under S1 (anabolic agents), S2 (peptide hormones / growth factors / mimetics — elamipretide is not a hormone analogue or GH-axis agent), S3 (β2-agonists), or S5 (diuretics / masking agents) [Anti-doping document — WADA 2026 Prohibited List].
Most plausible classification: S0 (Non-Approved Substances) when used outside its single FDA-approved indication (Barth syndrome, ≥30 kg). The S0 catch-all expressly captures “any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use.” For non-Barth use (longevity, performance, AMD, PMM), elamipretide is unapproved and therefore covered by S0. For Barth-syndrome use in athletes, a Therapeutic Use Exemption (TUE) pathway applies.
S4 (Hormone and Metabolic Modulators). WADA added BAM15 (mitochondrial uncoupler) and 7,8-benzoflavone to S4 in 2026. Elamipretide was not added to S4 in 2026; explanatory notes broaden examples of metabolic modulators. Status uncertain; monitor 2027 List.
In-/out-of-competition. S0 substances are banned at all times.
TUE eligibility. Theoretically available for the approved Barth-syndrome indication and conceivably for documented primary mitochondrial myopathy with appropriate medical documentation, per Article 4.4 of the World Anti-Doping Code. No published TUE precedent for elamipretide identified.
WADA 2026 Monitoring Program: Elamipretide not listed.
NCAA banned-drug-class status. The 2025–2026 NCAA banned-substance list does not name elamipretide. Peptide / metabolic-modulator class language is broad enough to capture it under non-approved or “chemically related” framing. Treat as banned for collegiate athletes; verify with NCAA at the relevant academic year.
DoD-OPSS Prohibited Dietary Supplement Ingredients list: Elamipretide is not specifically listed as of 2026-05-15. Operation Supplement Safety predominantly covers supplements; injectable prescription-only peptides are addressed under DoD Instruction 6130.06 and Service-specific policies (banned as unapproved drugs).
Global DRO (globaldro.com) check date: 2026-05-15. Elamipretide is not returned by name; database scope limited to listed brand/generic medications.
BSCG advisory: BSCG explicitly names “SS-31” alongside SLU-PP-332, retatrutide, Selank, Semax in its 2026 guidance as research peptides that would qualify as prohibited under WADA if detected in athletes [Anti-doping document — BSCG 2026 commentary].
Detection window. No published athlete-doping case for elamipretide as of 2026-05-15. The molecule is small (639.8 Da), with predicted urinary excretion of parent and two metabolites (M1, M2) within hours; targeted LC-MS/MS assays for cardiolipin-binding tetrapeptides can detect the parent compound. Estimated detection window in urine: hours-to-days from single dose; longer with repeated daily dosing. No published validated WADA-accredited assay for elamipretide has been identified.
Notable sanctions / precedents: None identified as of 2026-05-15.

4.3 Last regulatory review

Last regulatory review: 2026-05-15

5. Formulations and Routes

Formulation	Route	Status	Dosing studied	Source
Elamipretide HCl 80 mg/mL solution (280 mg / 3.5 mL vial, multi-dose, benzyl-alcohol preserved)	Subcutaneous, once daily	Approved (Forzinity, US, Sept 2025) for Barth syndrome ≥30 kg	40 mg SC qd (20 mg if eGFR <30)	[Regulatory — Forzinity label §3]
Aqueous solution for IV infusion	Intravenous	Investigational; used in early cardiac and PMM trials	0.005–0.25 mg/kg/h (4-h infusion or 5-day repeat)	[Peer-reviewed — Gibson 2016; Karaa 2018] ⚠️
1% Topical ophthalmic solution	Topical eye drop	Investigational; LHON Phase 2 completed (failed primary)	1% twice daily, both eyes	[Clinical trial registry — NCT02693119]
SC 40 mg pre-filled syringe	Subcutaneous	Used in ReCLAIM, ReCLAIM-2, MMPOWER-2, MMPOWER-3, TAZPOWER, PROGRESS-HF, ReNEW	40 mg qd	[Clinical trial registry — multiple]
Oral / intranasal	—	No oral or intranasal formulation clinically advanced; poor expected oral bioavailability for a peptide	n/a	—

The only approved formulation in any jurisdiction is the 80 mg/mL SC solution marketed in the US as Forzinity. All other formulations remain investigational.

6. Preclinical Evidence

Most foundational mechanistic and disease-model work originated in the Szeto laboratory at Cornell 🔴; an expanding body of independent replication exists primarily for aged-tissue and neurodegeneration models.

Cardiolipin binding (biophysics). High-affinity binding demonstrated with polarity-sensitive fluorescent analogues; lipid-bilayer surface-charge-dependent partitioning [Birk 2013 JASN] 🔴. Independent biophysical replication confirming electrostatic interaction and surface-potential modulation [Mitchell 2020 J Biol Chem — UConn / Alder laboratory, with Szeto as co-author].
Cardiac ischaemia-reperfusion. Reduction of infarct size and preservation of mitochondrial cristae in rodent and canine I/R models [Kloner 2012; Brown 2014; Allen & Pennington 2020 Commun Biol — Pennington-laboratory independent replication of cristae preservation in rat hearts following I/R].
Acute kidney injury (renal I/R, unilateral ureteral obstruction). Accelerated ATP recovery and reduced fibrosis [Szeto 2011 JASN; Birk 2013 JASN] 🔴.
Atherosclerotic renal-artery stenosis. Improvement in renal oxygenation in pilot human pharmacology study (Saad 2017, single arm, n=14) ⚠️.
Aged skeletal-muscle / sarcopenia models. Improved fatigue resistance and force production in aged mice within hours-to-days [Siegel 2013 Aging Cell PMID 23802411] 🔴. Independent replication in a 2025 Aging Cell paper (PMC12151887) — 8-week ELAM treatment in C57BL/6J aged mice partially reversed frailty index, improved cardiac strain and diastolic function, and improved skeletal-muscle fatigue resistance, but no statistically significant change in DNA-methylation or transcriptomic biological-age clocks was detected.
Cerebromicrovascular / cognitive aging. 2025 GeroScience (Springer 11357-025-01634-5) — preclinical screening of SS-31 for protection against cerebral microhaemorrhages in aged mice; functional benefit reported with explicit author note that the Szeto-laboratory mechanistic literature dominates the field.
Barth syndrome (tafazzin-deficient cellular models). Improved oxidative phosphorylation and partial restoration of cardiolipin profile in tafazzin-knockdown cardiomyocytes; foundational work at Johns Hopkins (Vernon lab) with NIH F31 funding (independent of Stealth for cell-modelling phase) — later clinical work funded by Stealth ⚠️.
Mitochondrial trifunctional protein (HADHA/HADHB) deficiency. Improved respiration in patient-derived fibroblasts and TFP-deficient mouse model (2025, PMC12779498) — independent replication of a respiratory benefit.
Neurodegeneration models. ALS (SOD1-G93A), Parkinson’s (α-synuclein), Alzheimer’s (Aβ-tau), traumatic optic neuropathy — multiple groups report attenuation of mitochondrial dysfunction, oxidative stress, and apoptosis biomarkers (review PMC8801496, 2022) 🔴 with mixed independent replication.
Retinal dystrophy / AMD models. ABCA4-deficient and laser-induced GA models show photoreceptor preservation; this work substantially overlaps with sponsor-funded Stealth ophthalmology programmes ⚠️.

7. Clinical Evidence

Cochrane systematic reviews: No Cochrane SR of elamipretide identified as of 2026-05-15. Cochrane reviews on mitochondrial-disease therapy more broadly (Pfeffer et al., CD004426) pre-date the major elamipretide trials.

7.1 Cardiac reperfusion — EMBRACE-STEMI (Phase 2a)

EMBRACE-STEMI (NCT01572909; Gibson CM et al., Eur Heart J 2016;37(16):1296–1303, PMID 26586786) ⚠️. Multicentre RCT, n=297, first-time anterior STEMI undergoing primary PCI, randomised to IV elamipretide 0.05 mg/kg/h or placebo for 1 h pre-reperfusion. Primary endpoint missed: no significant reduction in CK-MB AUC₀–₇₂. Safe and well tolerated. A small (n=19) post-hoc sub-study reported reduction in serum HtrA2 (Hortmann 2019 Eur Heart J Acute Cardiovasc Care PMID 30859853) — exploratory biomarker only.

7.2 Heart failure — PROGRESS-HF (Phase 2)

PROGRESS-HF (Butler J et al., J Card Fail 2020;26(5):429–437, PMID 32068002) ⚠️. RCT in stable HFrEF (LVEF ≤40%), n=71, 4-week SC daily elamipretide 4 mg or 40 mg vs placebo. Primary endpoint missed: no difference in change in LV end-systolic volume by cardiac MRI. Well tolerated. A companion RESTORE-HF (HFpEF) programme was initiated but has not produced a published positive pivotal readout; the broader heart-failure development programme was effectively de-prioritised.

7.3 Primary mitochondrial myopathy — MMPOWER series

MMPOWER (Phase 1/2) — Karaa A et al., Neurology 2018;90:e1212, PMID 29500292 ⚠️. n=36 adults with genetically confirmed PMM. IV 5-day dose-escalation. Highest-dose (0.25 mg/kg/h) group showed significant 6MWT improvement vs placebo. Hypothesis-generating; effect did not persist 2 days after cessation.
MMPOWER-2 (Phase 2 crossover) — Karaa A et al., J Cachexia Sarcopenia Muscle 2020;11:909, PMID 32096613 ⚠️. n=30, SC 40 mg/day, 4-week crossover. Primary 6MWT endpoint not statistically significant (19.8 m, 95% CI −2.8 to 42.5; p=0.083); secondary “most bothersome symptom” PMMSA improved.
MMPOWER-3 (Phase 3) — Karaa A et al., Neurology 2023;100:e768, PMC10382259 ⚠️. n=218, 24-week SC 40 mg/day. Both co-primary endpoints failed (Δ6MWT and PMMSA Total Fatigue Score). Pre-specified nuclear-DNA (nDNA) subgroup (n=56) showed positive 6MWT signal.
MMPOWER-3 post-hoc — Karaa A et al., Orphanet J Rare Dis 2024;19:431, PMID 39574155 ⚠️. nDNA replisome-disorder subgroup with CPEO showed significant 6MWT benefit (Δ +37.3 vs −8.0 m, p=0.0024). Exposure–response correlation. Used to design NuPOWER Phase 3 (fully enrolled, 2025).
Open-label extension — long-term safety/tolerability favourable at up to 260 weeks ⚠️.

7.4 Barth syndrome — TAZPOWER

TAZPOWER (NCT03098797) — Thompson WR et al., Genet Med 2021;23:471 (randomised crossover, n=12); Thompson 2024 (168-week OLE) ⚠️. 28-week double-blind placebo-controlled crossover followed by ≤192-week OLE.

Primary endpoints in the randomised crossover phase were NOT met (6MWT and BTHS-SA score).
Open-label extension showed cumulative 6MWT gain ~96 m at week 168, knee-extensor strength gains, and supportive echocardiographic and biomarker (cardiolipin / MLCL) data; 8 of 10 patients reached week 168, 3 of 8 reached 192 weeks.
The natural-history comparator study SPIBA-001 (retrospective NHC) ⚠️ provided the comparator dataset that the FDA initially rejected (CRL 2021 RTF; second CRL May 2025) but ultimately accepted with the addition of the knee-extensor-strength intermediate endpoint for accelerated approval. This is the dataset underpinning the 2025-09-19 approval.

7.5 Ophthalmology — ReCLAIM, ReCLAIM-2, LHON

ReCLAIM Phase 1 (NCGA dry AMD) — Allingham MJ et al., Ophthalmol Sci 2021;2(1):100095 ⚠️. Open-label, single-arm; supportive ellipsoid-zone preservation signal in 24-week assessment.
ReCLAIM-2 Phase 2 (NCT03891875) — Ophthalmol Sci 2024, PMID 39605874 ⚠️. n=176, 48-week SC 40 mg/day vs placebo in non-central GA. Both co-primary endpoints failed: change in low-luminance BCVA and Sqrt-GA area not significantly different from placebo. Prespecified analyses: significant slowing of EZ-attenuation progression (47% reduction, p=0.004) and categorical ≥2-line LLVA gain (p=0.04). Provided rationale for ReNEW Phase 3 (NCT06373731, n=360, 96 weeks, ongoing).
LHON Phase 2 (NCT02693119) — Karanjia R et al., Ophthalmology 2024;131:422, PMID 37923251 ⚠️. n=12, 1% topical ophthalmic solution, 52-week DBV-controlled + OLE. Primary BCVA endpoint not met; post-hoc central visual-field mean-deviation improvement and OLE color-discrimination / contrast-sensitivity gains.

7.6 Other indications

Atherosclerotic renal-artery stenosis — Saad A et al. (2017) — small pilot, exploratory ⚠️.
PREVIEW HFrEF — early Phase 1 IV (NCT02388464) ⚠️.

7.5 Disputed Claims

Dispute 1: “ROS scavenger” vs “cardiolipin chaperone / electrostatic modulator” framing. The original 2004 publication (Zhao et al., J Biol Chem) and several follow-on papers framed SS-31 as a “cell-permeable peptide antioxidant.” By 2013–2020, the Szeto laboratory and collaborators had publicly abandoned the direct-scavenger model, arguing instead that SS-31 binds cardiolipin and reduces electron leak — the antioxidant effect is indirect. Mitchell, Alder et al. (J Biol Chem 2020, PMID 32209654, UConn — published with Szeto as senior co-author) state that SS-31 does not function as a stoichiometric ROS scavenger. Both sides: the scavenger framing persists in third-party reviews, vendor materials, and some sponsor-adjacent communications; the cardiolipin/electrostatic framing is the current Szeto-laboratory and FDA-label position. Funding flag: the rejection of the scavenger framing was authored partly by the originating laboratory itself, complicating the “independent dispute” structure. 🔴

Dispute 2: EMBRACE-STEMI null result vs positive preclinical cardiac I/R data. Robust preclinical effect sizes in rodent / canine I/R models (Kloner 2012; Brown 2014; multiple Szeto papers 🔴) did not translate in the 297-patient Phase 2a EMBRACE-STEMI trial (Gibson 2016 PMID 26586786) ⚠️. This is a classic translational-failure pattern. Stealth’s published interpretation emphasises dosing, timing of administration relative to reperfusion, and patient-selection (sub-study showed reduction in HtrA2, an exploratory mitochondrial-apoptosis marker — Hortmann 2019) ⚠️. No reconciling mechanism distinguishing responders from non-responders has been formally validated, and the cardiac-reperfusion development arm has not been resumed.

Dispute 3: MMPOWER-3 primary-endpoint miss vs sponsor and AdCom defence. MMPOWER-3 (Karaa 2023) ⚠️ failed both co-primary endpoints in the overall 218-subject population. Sponsor and academic investigators argued for a genotype-specific responder hypothesis (nDNA-replisome / CPEO subgroup), publishing post-hoc support (Karaa 2024 Orphanet J Rare Dis PMID 39574155) ⚠️ and designing NuPOWER to test prospectively. The FDA CRDAC discussion (10 October 2024) on Barth syndrome split 10-6 in favour, with the dissent arguing that the small TAZPOWER population and natural-history comparator did not constitute substantial evidence of effectiveness in the conventional sense [Regulatory — CRDAC transcript, FDA-2024-N-3939]. Patient-advocacy testimony (Barth Syndrome Foundation, MitoAction, UMDF) was heavily weighted in the eventual accelerated-approval pathway. The pre-AdCom FDA briefing document was openly skeptical and characterised the data package as unlikely to support traditional approval; the final accelerated-approval decision relied on knee-extensor muscle strength as an intermediate clinical endpoint added during the resubmission cycle.

Dispute 4: Single-group dependency 🔴. A large fraction of the mechanistic literature — and a substantial share of the early translational disease-model literature — traces to the Szeto laboratory at Weill Cornell Medical College and the collaborating Schiller laboratory at the Clinical Research Institute of Montreal. Genuinely independent confirmation of the central cardiolipin-binding biophysics is limited; the Mitchell/Alder 2020 J Biol Chem paper is the most prominent independent biophysical replication and includes Szeto as co-author. Aged-tissue replication (Marcinek lab, Rabinovitch lab — University of Washington) is partially independent but historically collaborates with Szeto. As of 2026-05-15, fully independent replication of high-affinity cardiolipin binding with no Szeto-laboratory co-authorship is sparse.

Dispute 5: Independent clinical replication. All registrational and supportive clinical trials (MMPOWER-1/2/3, TAZPOWER, EMBRACE-STEMI, PROGRESS-HF, ReCLAIM, ReCLAIM-2, LHON) are Stealth-sponsored. No fully independent academic-investigator-initiated Phase 2/3 RCT of elamipretide has been identified. Normal for a single-asset orphan-drug developer but methodologically relevant.

7B. Community Evidence Layer

Adoption and trajectory

SS-31 first surfaced in the optimization audience around 2014–2016, when Bendavia heart-failure Phase 2 readouts were circulating on EliteFitness, AnabolicMinds and early MESO-Rx peptide subforums. Conversation stayed close to the Szeto/Schiller cardiolipin-binding rationale; the compound was difficult to source. A second wave hit during the 2018–2022 ReCLAIM / ReCLAIM-2 dry-AMD trial era, when older biohackers and r/macular_degeneration self-experimenters began asking how to obtain it. The current 2024–2026 wave is driven by (a) widely-available research-grade powder from underground Chinese-synth vendors, (b) podcast amplification (Vigorous Steve, Peter Attia, Jay Campbell), and (c) the FORZINITY headlines used by the community as a credibility anchor against skeptics (“you do know that SS-31 has an FDA approved version called Forzinity… that costs $61,000 per month” — ostrichsak, MESO-Rx, May 2026).

Two non-overlapping subcommunities drive adoption: longevity / mitochondrial-medicine users (typically 40+, stacking with NAD+ precursors, MOTS-c, urolithin A) and performance / bodybuilding users on MESO-Rx (running SS-31 alongside AAS cycles, GLP-1s, SLU-PP-332). A smaller third group — dry-AMD and Barth-syndrome patients — appears on r/macular_degeneration and r/Cardiomyopathy but operates through medical channels (Transcend, compounding pharmacies, Forzinity prescriptions at ~$61k/mo). Trajectory: rising sharply in 2025–2026. Within the mitochondrial-peptide class, SS-31 has noticeably more codified protocol discussion than MOTS-c, humanin, or SBT-272 (the last being nearly invisible in community forums).

Documented protocols

Source	Date	Dose	Frequency / Cycle	Route	Notes
MESO-Rx — Ugandafred	May 7 2026	3 mg SS-31 + 2 mg MOTS-c	Daily, 8–12 wk	SubQ	Synergy framing
MESO-Rx — anonymous	2026	5 mg	Daily, ongoing	SubQ	”Optimal for benefits and financial efficiency”
MESO-Rx — Nidus	Jan 28 2026	15 mg	Daily, 3 mo	SubQ	”Amazing experience overall”
MESO-Rx — Here2Learn	Feb 1 2026	Titrating to 20 mg/day	Daily, long-term	SubQ	Cites unverified “Mayo Clinic private trial” at 60–100 mg/day
MESO-Rx — touringsedan	Feb 1 2026	40 mg	Daily, 6 mo	SubQ	”Only dose used on humans” heroic-dose position
MESO-Rx — SmallTitsIRL	Jan 28 2026	1–5 mg pre-workout/cardio	Daily	SubQ	Low-dose-pre-cardio camp
GLP-1 Forum — “14-week protocol”	2026	SS-31 first 6 wk → MOTS-c 5 mg M/W/F	14 wk total (sequential)	SubQ	”SS-31 rebuilds damaged mitochondria, MOTS-c then recharges them”; +600 mg NR daily
Vigorous Steve YouTube	Jul 15 2025	Discussion-level	—	SubQ	SS-31 + MOTS-c + SLU-PP-332 trio
Jay Campbell write-up	2024–25	”8–12-week cycle costing thousands”; references trial 40 mg	Daily, 8–12 wk	SubQ	Commercial-affiliated; concedes no reliable affordable vendor at clinical purity
Injectco / Peptide Initiative protocols	2026	2.5 mg starter, 5 mg standard, 7.5–10 mg responder ceiling	Daily morning, 12 wk	SubQ	Reconstitution: BAC water, refrigerate, never freeze, 28-day window

Protocol spread. The community is openly split into three camps: (1) low-dose 1–5 mg/day “feel it in cardio,” (2) moderate-dose 10–20 mg/day longevity users running 8–12-week cycles, (3) heroic-dose 30–60 mg/day (occasionally 100 mg/day cited via unverified “Mayo private trial”) who argue only trial-level doses produce reproducible effects. Reconstitution practice is uniform: BAC water, refrigerate, never freeze post-recon, 28-day window, rotate sites. Oral and intranasal routes are essentially absent from the community — everyone is injecting subQ.

Claimed effects

Subjective “cleaner” energy / reduced fatigue — common (Ugandafred, amazonas, Vigorous Steve).
Cardio / endurance improvement (lower HR at same workload) — common; attribution split between SS-31 and MOTS-c when stacked (xelatothe MESO-Rx May 10 2026 attributes the HR effect specifically to MOTS-c on Oura/Garmin, illustrating the attribution problem).
Kidney repair / recovery from kidney injury — occasional but emphatic where it appears (MapleAUS May 7 2026; massgainer87 Feb 25 2026).
Cognitive endurance / reduced brain fog during long focus tasks — common (paraphrased r/Peptides 2024 commentary via Real Peptides aggregator: “you notice it three hours into focused work when you haven’t hit the wall yet” — original Reddit thread not directly retrieved).
Anti-aging / “raised baseline” rather than acute effect — widespread framing (Jay Campbell; PeptideFox “Mito Stack”).
Dry AMD / vision improvement — single-source within strict community forums; most AMD discussion routes to medical-channel patients.
Recovery from oxidative stress / overtraining — common (PeptideFox; Swolverine).
Fat-loss adjunct during cut — occasional (Ugandafred May 2026).

Reported side effects

Fatigue / “made me tired” / need-a-nap — surprisingly common counter-effect at moderate doses (BeardedGuy, SwampNut, Cita on MESO-Rx). Community-proposed workaround: methyl donor (TMG 750–1500 mg) co-administration (Here2Learn Feb 2026).
Injection-site reactions (erythema, pruritus, induration, bruising) — common, mild and self-limited; mirrors published trial AE tables.
Headache — occasional, mild, dose-related.
Transient nausea / GI — occasional, typically at higher doses (10 mg+).
Flushing — single-source, mild, transient (Injectco 2026).
“Nothing at all” / null response — reported frequently enough to function as its own AE class (nxckf, level3 — both MESO-Rx Jan 28 2026).
No serious AEs reported in community discussion at the doses being run.

Community dissent

The SS-31 community is unusually split, and the splits do not smooth out:

“Does it actually work in healthy users?” — thejumpingsheep argues SS-31 is part of the peptide hype wave driven by GLP-1 success and that “OTC supplements will outperform this in healthy people.” ostrichsak counters with the FORZINITY argument. The benefit / no-benefit split appears to correlate with age (level3 Jan 28 2026: “people who rave about SS-31 are older — especially 50+”).
Price/mg justification — Proud Pangolin (Jan 28 2026) prices 10×50 mg kits at $330; nxckf in the same thread says “might as well just inject BAC water.” Internal disagreement on whether SS-31 is worth ~10× the per-mg price of BPC-157 or MOTS-c.
Indistinguishable from MOTS-c? — Stevemavrick (May 8 2026): “Mot-C is hit or miss. Ss-31 = more behind the scenes stuff mitochondria/oxidative stress. Not really something you feel.” amazonas reports the opposite. Stevemavrick concedes that responsiveness varies. No convergence.
Heroic vs wellness dose — touringsedan: “40 mg/day was the only dose used on humans”; Mr.AAJR rebuts: “40 mg was used in the trials because it is used to treat Barth Syndrome, a SEVERE mitochondrial dysfunction. Not because lower doses don’t work.” Unresolved; shapes most cost-management threads.
Stealth’s clinical history — community read varies. Some users cite FORZINITY as ratification; others quietly note ReCLAIM-2 and MMPOWER-3 missed primary endpoints (thejumpingsheep: “human trial that concluded didn’t translate to any actual improvements in fatigue resistance”).
Placebo / mechanism-vs-experience gap — repeatedly raised (Jayswizzle May 7 2026: “those were coming from people on Instagram or YouTube. So it’s hard to tell who’s right or who’s getting paid to promote stuff”).

Stack patterns

SS-31 + MOTS-c — the headline 2025–2026 pairing. SS-31 loaded for 4–6 weeks first to “repair/stabilize” mitochondrial membranes, MOTS-c then “recharges” or signals biogenesis on the repaired foundation. Documented across MESO-Rx threads, Vigorous Steve podcast episodes, PeptideFox “Mito Stack.”
Mitochondrial trio — SS-31 + MOTS-c + SLU-PP-332. Vigorous Steve.
+ NAD+ / NR / NMN. Universal background. PeptideFox names NAD+ the third leg explicitly. Community disagrees on form: Ugandafred argues injectable NAD+ is “pointless” and oral NMN/NR is preferable.
+ Methyl donors (TMG). Community-developed workaround for the fatigue AE — Here2Learn, Proud Pangolin (Feb 2026).

Vendor / supply context

Tier	Source type	Price/mg
Underground raw-powder kit	MESO-Rx Jan 2026 anecdote	~$0.66/mg
Bulk 50 mg research vial	Limitless Peptides, Maylips, etc.	~$3.50–$6.40/mg
Small 5–10 mg vial	PureRawz, smaller vendors	~$17–$28/mg
Compounded prescription	Transcend / wellness clinics	typically $300–$800/month
FDA-approved Forzinity	Stealth specialty distribution	~$61,000/month

Active vendors as of May 2026 include Limitless Peptides (with Janoshik batch verification), Pure Rawz, Maylips, Peptide Partners, Cosmic Peptides, Beyond Peptides, Core Peptides, Verified Peptides, Nextech Labs, Pure Health Peptides, and Amino Asylum (catalog-level). Peptide Sciences, historically a top SS-31 retailer, has voluntarily shut down. Wuhan Wansheng Biotechnology (“WWB”) is referenced as a raw-powder source.

Research-grade SS-31 sits at roughly 5–10× the per-mg price of BPC-157, 2–3× MOTS-c, and orders of magnitude above tirzepatide on a per-mg basis. Multiple MESO-Rx commenters cite it as “the most expensive peptide I run.”

QC issues raised:

D-Arg vs L-Arg substitution. PeptideDeck and Real Peptides both warn that the D-arginine residue is sometimes substituted with cheaper L-isomer, which would lose cardiolipin selectivity. No named HPLC-busted batch surfaced, but the concern is repeated.
Truncated/deletion-sequence contamination. Generic “95% TPC” labels may hide only 80% target-sequence purity.
Lyophilization quality / pre-mixed solutions degrading. Community consensus: avoid pre-mixed SS-31 solutions, reconstitute fresh.
Janoshik third-party COA practice is the community-trusted credibility play; vendor-supplied COAs are treated as unreliable.

Community Score

Component	Score
Usage volume	15/25
Protocol codification	13/25
Reported effect consistency	10/25
Time in circulation (~10–12 years)	18/25
Total	56/100
Community Tier	C

8. Safety Profile

From the Forzinity label (NDA 215244, 2025-09-19) [Regulatory — FDA Forzinity prescribing information] and pooled clinical-trial data:

Most common adverse reactions. Injection-site reactions (ISRs) — 100% of treated Barth-syndrome patients in TAZPOWER vs 67% on placebo (cross-binding to placebo arm in crossover design). Erythema (100% vs 25%), induration (67% vs 17%), pain, pruritus, bruising, urticaria. ISRs typically begin with first dose, persist throughout treatment, and resolve within hours of last dose (rarely up to 14 days). Across MMPOWER-3 and ReCLAIM-2 (larger n), ISRs were the dominant AE class and generally mild-to-moderate ⚠️.

Serious / important warnings.

Benzyl-alcohol toxicity. Forzinity contains benzyl alcohol 20 mg/mL as preservative. Contraindicated in neonates (gasping syndrome / metabolic acidosis risk).
Hypersensitivity reactions including serious allergic reactions requiring emergency intervention. Skin (rash, papular lesions, eczematous dermatitis) and respiratory (cough) symptoms. Onset minutes to months after initiation. Permanent discontinuation required for serious reactions.
Other AEs reported in trials: headache, nausea, dizziness — class background, generally mild ⚠️.

Community-layer AE not in trials: paradoxical fatigue. Multiple MESO-Rx posters at moderate doses (5–20 mg/day) report “made me tired” / “have to nap” as the dominant subjective response. This is not characterised in any regulated trial and may reflect cohort differences (healthy users vs Barth/PMM patients), dose context, or selection bias. The community-proposed workaround is TMG 750–1500 mg co-administration. No published clinical confirmation exists.

Special populations (Forzinity label).

Pregnancy / lactation. Limited human data; animal repro-tox studies in rats at ~5× MRHD did not show adverse fertility/reproductive effects. Excretion in human milk unknown.
Pediatric use. Approved ≥30 kg. Not approved for neonates (benzyl-alcohol warning). Most TAZPOWER experience age 12–35 years.
Geriatric. Limited data.
Renal impairment. No dose adjustment for mild/moderate (eGFR ≥30). Dose reduced to 20 mg SC qd for severe (eGFR <30) not on dialysis. Insufficient data for dialysis-dependent patients. Elamipretide and metabolites M1, M2 accumulate with renal impairment.
Hepatic impairment. No hepatic metabolism observed in vitro; no adjustment expected.

Genotoxicity / carcinogenicity. Negative in Ames, CHO chromosome-aberration, and rat bone-marrow micronucleus assays. No carcinogenicity data published. ⚠️

Retraction Watch search (2026-05-15). No retracted elamipretide papers identified.

9. Drug Interactions

From the Forzinity label [Regulatory — FDA Forzinity §7, §12.3]:

No clinically significant CYP-mediated metabolism. Elamipretide is not metabolised by major CYP enzymes in vitro.
CYP inhibition / induction (in vitro). Does not meaningfully inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 3A; does not induce CYP1A2, 2B6, 3A4.
Drug transporters. Does not inhibit OCT2, BCRP, OAT1, OAT3, OATP1B1, OATP1B3, P-gp, or MATE2-K at clinical exposures.
Pharmacodynamic / theoretical interactions. No formal interaction studies with other mitochondria-active drugs (statins, metformin, amiodarone, idebenone, coenzyme Q10, dichloroacetate). Co-administration with idebenone or other mitochondrial-targeted agents has not been formally studied.
Community-original protocols. TMG co-administration (1.5 g pre-dose) for fatigue mitigation, MOTS-c stacking, NAD-precursor stacking — none have published interaction data.
Bottom line. Low pharmacokinetic-interaction profile is expected based on PK characterisation, but the absence of dedicated DDI studies with mitochondrial-active agents is a clinical-practice gap.

10. Research Gaps

Independent mechanistic replication. Reliance on the Szeto-laboratory output for the core cardiolipin-binding mechanism remains structurally heavy 🔴; independent biophysical work (Mitchell/Alder 2020) is the most rigorous external check but includes Szeto co-authorship. Truly Szeto-independent confirmation of cardiolipin binding affinity, site, and stoichiometry is sparse.
Pattern of failed primary endpoints. EMBRACE-STEMI, MMPOWER-2 (formal primary p=0.083), MMPOWER-3, PROGRESS-HF, ReCLAIM-2, LHON SPILH-201, and the randomised portion of TAZPOWER all missed pre-specified primary endpoints. Open-label extensions and post-hoc subgroup analyses generated the principal regulatory and clinical narrative. The accelerated-approval Barth-syndrome decision relies on an intermediate clinical endpoint (knee-extensor strength) introduced in the resubmission cycle. Confirmatory evidence pending.
Mechanism-disease mismatch. Whether the same cardiolipin-stabilisation mechanism plausibly explains efficacy across cardiac I/R, HF, PMM, Barth syndrome, dry AMD, LHON, and aging — disease processes with very different mitochondrial pathology — is not clearly established.
Pediatric safety beyond Barth syndrome ≥30 kg. No paediatric data below 30 kg; no neonatal data; benzyl-alcohol formulation precludes paediatric expansion without reformulation.
Long-term safety > 4 years. Longest exposure is the TAZPOWER OLE (~192 weeks, n=3). Population-level long-term safety after broader use post-approval is unknown.
Head-to-head data. No comparator trials against idebenone (approved for LHON in EU), CoQ10, or other mitochondrial agents.
Confirmatory trial commitments. FDA accelerated approval is contingent on confirmatory trial(s) for Barth syndrome not publicly specified in detail as of 2026-05-15.
503A grey-market quality control. With elamipretide now an FDA-approved product but active community use sourced through research-peptide vendors, the gap between approved-drug quality (USP-grade, controlled benzyl-alcohol formulation, validated dose form) and research-chemical-vendor product is structurally relevant. No published analytical-quality survey of research-grade SS-31 has been identified. Specifically: the D-Arg vs L-Arg substitution risk flagged by PeptideDeck and Real Peptides has no published HPLC-confirmation case in the literature.
The healthy-user / longevity use case has zero controlled human evidence. Aged-mouse functional gains are short-duration and uncoupled from epigenetic-clock changes (2025 Aging Cell). No human RCT in aging, longevity, sarcopenia, or performance endpoints exists.
The community-reported paradoxical fatigue AE has no regulated-trial confirmation or mechanistic characterisation. This is a community-only signal in a population (healthy users) the regulatory trials did not study.

11. Bottom-Line Encyclopedia Note

Elamipretide (SS-31 / MTP-131 / Forzinity) is a Szeto–Schiller mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. Until 19 September 2025 it had no approved indication anywhere; the FDA accelerated approval for Barth syndrome (≥30 kg) — the first approved mitochondria-targeted therapeutic globally — relies on a small randomised crossover trial (TAZPOWER, n=12) and a natural-history comparator, with an intermediate endpoint of knee-extensor strength. The CRDAC vote was 10-6; the FDA initially issued a CRL. Across PMM (MMPOWER-3), HFrEF (PROGRESS-HF), STEMI reperfusion (EMBRACE-STEMI), LHON, and dry AMD (ReCLAIM-2), the compound has missed primary endpoints in pivotal RCTs. Mechanistic literature is heavily Szeto-laboratory dependent. Community use as a longevity / performance peptide via research-chemical channels remains unsupported by controlled human evidence outside Barth syndrome; under WADA, off-indication use falls under S0 (banned at all times for in-jurisdiction athletes).

11B. Gap Analysis — Where Science and Community Diverge

For the Barth-syndrome indication, the gap pattern is convergent at low amplitude (Science B/37, Community modest — Barth is not the community use case). For the longevity / performance optimization indication that the encyclopedia audience cares about, the pattern is High community + Low science, “untested” subclass: Science D/8, Community C/56. The community is using a regulator-approved molecule (the approval is real and material — Forzinity exists, costs $61k/month, and serves as a clinical credibility anchor) for an indication the regulator has not approved and the clinical programme has not tested, while transferring inference from disease-population trials that themselves missed primary endpoints.

Topic	Science layer	Community layer	Gap
Longevity / healthy-aging / sarcopenia — the community use case	No controlled human evidence. Aged-mouse functional gains exist but are short-duration and uncoupled from epigenetic-clock changes (2025 Aging Cell).	Codified 8–12-week protocol; “raised baseline” framing; SS-31 + MOTS-c headline stack.	🔴 Untested. The community is not wrong about the absence of negative data in healthy users; it is wrong about the presence of positive data. Closest support is preclinical aged-rodent work, not human.
Dose	All registrational and supportive trials used 40 mg SC qd (or weight-equivalent IV). Single dose validated.	Three-way split: 1–5 mg / 10–20 mg / 30–60 mg. No consensus. The Mr.AAJR vs touringsedan exchange on MESO-Rx is the canonical unresolved dose dispute.	Community is dosing across a 30-fold range with no controlled signal of where the effect actually sits in healthy users. The 40 mg figure comes from a severe-disease population (Barth/PMM); whether lower doses do nothing or are sufficient in healthy users is unknown.
Mechanism	Cardiolipin chaperone / electrostatic IMM modulator (current Szeto-laboratory + FDA-label position). ROS-scavenger framing abandoned by the originating lab post-2013.	Both framings circulate in vendor materials and third-party reviews; the older antioxidant framing persists in community marketing.	Community materials lag the science by ~10 years on mechanism. This matters because the “antioxidant” framing supports broader marketed indications than the cardiolipin-chaperone framing does.
Effect attribution in stacks	All registrational trials are SS-31 monotherapy.	Headline use case is SS-31 + MOTS-c stack, often + NAD precursors, sometimes + SLU-PP-332. xelatothe explicitly attributes cardio HR effect to MOTS-c not SS-31.	The stack confounds every community effect claim. It is impossible from community reports to determine which mitochondrial peptide is producing which subjective effect.
WADA / anti-doping	S0 catch-all applies to off-Barth use; banned at all times. BSCG names SS-31 explicitly.	Discussed (Vigorous Steve, occasional MESO-Rx mentions) but not central to most clinic / biohacker framing.	Community-aware but underweighted. Anyone subject to drug testing — NCAA, military, USADA — needs to know this before the first dose. No published sanction precedent exists yet for elamipretide specifically, but the analytical method (LC-MS/MS) is straightforward.
Paradoxical fatigue AE	Not characterised in any regulated trial. Mechanism unknown.	Universally reported by a non-trivial minority at 5–20 mg/day. Community-developed TMG workaround.	Community-only signal that science cannot address because no regulated trial of SS-31 in healthy users exists. The mitigation protocol is community-original with no published validation.
Pattern of failed primary endpoints	EMBRACE-STEMI, PROGRESS-HF, MMPOWER-3 (overall pop.), ReCLAIM-2, LHON, randomised TAZPOWER all missed.	thejumpingsheep (May 2026) raises this directly; ostrichsak counters with FORZINITY-as-ratification argument; community internally split on what to make of the pattern.	The disagreement is real and the community is having the right argument. Both readings are defensible: a real approval exists in a rare-disease indication, AND the broader programme has missed most pivotal endpoints. Resolution depends on whether the reader treats accelerated approval as ratifying the molecule’s mechanism or as a regulatory accommodation for an ultra-rare population.
Single-group dependency	🔴 Szeto-laboratory dominance of mechanistic and early translational literature; Mitchell/Alder 2020 is the most prominent independent biophysical replication and still includes Szeto as co-author.	Not raised in community discussion; the FORZINITY approval is treated as external validation of the underlying mechanism.	Community is unaware of or unbothered by the single-group dependency. FDA approval reframes the dependency question for the community but does not resolve it scientifically — a regulator can approve a drug whose mechanism is dominated by one lab.
D-Arg vs L-Arg substitution risk	No published HPLC-confirmation case identified. Theoretical concern from medicinal-chemistry rationale (D-aa is the SS-design feature).	Repeatedly raised by PeptideDeck, Real Peptides; no named bust. Janoshik COA practice is the community-trusted mitigation.	Both layers agree on the concern; neither has the analytical data. This is a structural QC gap in research-chemical SS-31 that no peer-reviewed analytical-quality survey has addressed.
Mechanism-disease mismatch	One mechanism (cardiolipin stabilisation) is being applied across cardiac I/R, HF, PMM, Barth syndrome, dry AMD, LHON, aging — pathologies with very different mitochondrial signatures.	Not raised in community discussion; “mitochondrial healing” framing erases the distinction.	Community is extrapolating across a mechanism-disease mismatch the science has not formally addressed. If the cardiolipin-binding effect is selective for cardiolipin-rich cristae or specific to certain mitochondrial pathology subtypes, the longevity / general-mitochondrial extrapolation has weaker support than the Barth-syndrome data suggest.

Net characterisation. SS-31 / elamipretide sits in the High community + Low science, “untested with FDA-approval halo” subclass of the gap-pattern matrix. This is a distinctive gap pattern. Unlike BPC-157 (community ahead, no approval anywhere) or TB-500 (community confident in absence of relevant evidence, with two-molecule confusion), SS-31 has a real FDA approval that the community uses as a credibility anchor — but the approval is in a rare-disease indication that has nothing to do with the community use case, and the broader clinical programme has missed most of its primary endpoints. The two highest-consequence gaps:

There is no controlled human evidence in the indication the community cares about (general mitochondrial / longevity), and the community-running dose range (1–60+ mg/day) is 30-fold and unsettled. Aged-rodent data exists but is short-duration and does not move biological-age clocks.
The FORZINITY approval is being used as inferential support for the longevity use case in community discourse, when the approval rests on a 12-patient crossover trial with failed randomised-phase primary endpoints, an intermediate endpoint added during resubmission, and a 10-6 CRDAC vote.

12. Three Paths

You choose your risk tolerance. This monograph provides the data, not the recommendation.

Conservative path — wait. Defined as not engaging until at least one of (a) peer-reviewed publication of a Phase 2/3 RCT of elamipretide in any healthy-aging, longevity, sarcopenia, or performance endpoint with a positive primary; (b) marketing authorisation for elamipretide in any non-Barth indication in a major jurisdiction; (c) Phase 3 NuPOWER (PMM, nDNA-restricted) peer-reviewed positive primary readout, providing independent evidence that the mechanism translates to a non-rare-disease mitochondrial population; (d) ReNEW (dry AMD) Phase 3 peer-reviewed positive primary; (e) an FDA-approved indication relevant to optimization-audience use. None of these gates is met as of 2026-05-15. The general optimization use case does not meet the conservative bar.

Moderate path — Tier D with supervision (Barth/PMM-adjacent populations only). Defined as engaging only for documented mitochondrial pathology (Barth syndrome, primary mitochondrial myopathy, suspected mitochondrial disease workup) through (a) a Forzinity prescription where the Barth indication and ≥30 kg criterion are met, (b) a clinical-trial slot in NuPOWER, ReNEW, or comparable Stealth-sponsored programme, or (c) a licensed physician’s evaluation including baseline mitochondrial workup, on-cycle bloodwork, and renal function monitoring (eGFR <30 requires 20 mg/day dose reduction). The moderate path is not the general-optimization use case; it is the rare-disease and documented-mitochondrial-pathology use case under physician oversight. Drug-testing exposure: TUE-eligible for the approved indication; off-indication use is S0 banned at all times.

High-tolerance path — grey-market with mitigation. Defined as acknowledging that (a) none of the conservative gates is met, (b) WADA S0 applies to all off-Barth use with at-all-times prohibition, (c) the community use case has no human RCT support, (d) the dose-response is unresolved across a 30-fold community range, and (e) the paradoxical fatigue AE is real and unexplained. The community mitigation stack documented in Pass 2: Janoshik third-party COA verification (rather than vendor-supplied); reconstitution in BAC water, refrigerate, never freeze, 28-day post-recon window; start at lower end of community range (1–5 mg/day) rather than trial dose (40 mg) given the dose dispute; structured baseline + on-cycle bloodwork including renal function (eGFR) and CBC/CMP; if fatigue emerges, the community workaround is TMG 750–1500 mg, though this has no published validation; avoid stacking with MOTS-c, NAD precursors, or SLU-PP-332 in the first cycle so the SS-31 effect is attributable; cycle 8–12 weeks rather than open-ended; physician-monitoring dialogue even where the physician has not prescribed. Drug-testing exposure assessed honestly — collegiate / military / USADA athletes are exposed under WADA S0, with detection by targeted LC-MS/MS plausible within hours-to-days of dosing despite the absence of a published validated WADA assay.

13. Key References

Regulatory documents

FDA. Forzinity (elamipretide) prescribing information, NDA 215244, initial approval 2025-09-19.
FDA CDER Integrated Review, NDA 215244, 2025.
FDA Cardiovascular and Renal Drugs Advisory Committee, Docket FDA-2024-N-3939; meeting 2024-10-10; vote 10-6.
EMA Orphan designation EU/3/21/2430, Barth syndrome, 2021-05-20.
FDA PCAC dockets FDA-2025-N-6895 (June 2026) and FDA-2026-N-2979 (July 2026) — elamipretide not on agenda.
TGA Therapeutic Goods (Poisons Standard—February 2026) Instrument 2026.

Anti-doping documents

WADA 2026 List of Prohibited Substances and Methods, in force 2026-01-01.
BSCG 2026 WADA Prohibited List commentary (SS-31 named under non-approved peptides).

Peer-reviewed mechanistic / preclinical (foundational)

Zhao K et al. J Biol Chem 2004;279(33):34682–34690. PMID 15184369. 🔴
Birk AV et al. J Am Soc Nephrol 2013;24(8):1250–1261. PMID 23813215. 🔴
Szeto HH. Br J Pharmacol 2014;171(8):2029–2050. PMID 24329526. 🔴
Mitchell W, …, Szeto HH, Alder NN. J Biol Chem 2020;295(21):7452–7469. PMID 32209654.
Siegel MA et al. Aging Cell 2013;12(5):763–771. PMID 23802411. 🔴
Aging Cell 2025 (PMC12151887) — independent C57BL/6J aged-mouse 8-week ELAM treatment.
GeroScience 2025 (Springer 11357-025-01634-5) — cerebromicrovascular SS-31 screening.

Peer-reviewed clinical trials

Gibson CM et al. EMBRACE-STEMI. Eur Heart J 2016;37:1296–1303. PMID 26586786. (NCT01572909) ⚠️
Karaa A et al. MMPOWER. Neurology 2018;90:e1212. PMID 29500292. (NCT02367014) ⚠️
Karaa A et al. MMPOWER-2. J Cachexia Sarcopenia Muscle 2020;11:909. PMID 32096613. (NCT02805790) ⚠️
Karaa A et al. MMPOWER-3. Neurology 2023;100:e768. PMC10382259. (NCT03323749) ⚠️
Karaa A et al. MMPOWER-3 nDNA post-hoc. Orphanet J Rare Dis 2024;19:431. PMID 39574155. ⚠️
Thompson WR et al. TAZPOWER. Genet Med 2021;23:471. PMID 33077894. (NCT03098797) ⚠️
Thompson WR et al. TAZPOWER 168-week OLE. Genet Med 2024. ⚠️
Butler J et al. PROGRESS-HF. J Card Fail 2020;26:429. PMID 32068002. ⚠️
Allingham MJ et al. ReCLAIM. Ophthalmol Sci 2021;2(1):100095. ⚠️
ReCLAIM-2. Ophthalmol Sci 2024. PMID 39605874. (NCT03891875) ⚠️
Karanjia R et al. LHON Phase 2. Ophthalmology 2024;131:422. PMID 37923251. (NCT02693119) ⚠️
Hortmann M et al. HtrA2 sub-study. Eur Heart J Acute Cardiovasc Care 2019;8:695. PMID 30859853.

Clinical trial registry identifiers

NCT01572909 EMBRACE-STEMI · NCT02367014 MMPOWER · NCT02805790 MMPOWER-2 · NCT03323749 MMPOWER-3 · NCT03098797 TAZPOWER · NCT02693119 LHON SPILH-201 · NCT02848313 ReCLAIM · NCT03891875 ReCLAIM-2 · NCT06373731 ReNEW · NCT01755858 PREVIEW HF · NuPOWER (Phase 3 PMM, fully enrolled 2025).

Academic secondary sources

PubChem CID 11764719 (elamipretide free base); CID 137528200 (HCl); CID 155977543 (2TFA salt).
DrugBank elamipretide entry.

Community sources (Pass 2 layer)

MESO-Rx Forum threads: “MOTS-C & SS-31????” (Jayswizzle, Apr 30 2026; 51 replies / ~1K views); “Should you take lower dosages of SS-31…” (Proud Pangolin, Jan 28 2026; 19 replies / 561 views); “What are your experiences with MOTS-C?” page 2; “Starting Mots-C when stepping into my cruise”; “SS-31 raw powder vendor (price?)” (Swedishsteel, Jan 1 2026).
GLP-1 Forum “SS-31 or Mots-C with Reta” — 14-week protocol thread.
Meso-Morph Anabolic Steroids Forum “MOTS-C and Energy” thread.
Vigorous Steve YouTube / Podbean episodes: “Mots-C, SS-31 & SLU-PP-332 Stacks” (Jul 15 2025); “TEST & GH Extreme Bloating… SS-31 & Mots-C Synergy”; “Clenbuterol Builds Muscle? BPC-157 & TB-500 Year-Round? Cutting On SLU-PP-332, Mots-C, SS-31 & Tren?” (Jul 28 2025); “My Mitochondrial Stack - MOTS-c.”
Peter Attia Drive podcast SS-31 peptide case-study episode (chapter marker 18:15).
Jay Campbell “SS-31 The Mitochondria Peptide” guide ⚠️.
PeptideFox “SS-31, MOTS-c, and NAD+: The Mito Stack” ⚠️.
Swolverine “SS-31 Peptide (Elamipretide)” ⚠️.
Real Peptides aggregator articles (paraphrased r/Peptides 2024 thread content; original Reddit thread not directly retrieved).
PeptideDeck and The Peptide Catalog buying guides 2026 ⚠️.
Forge Biology, Innerbody, hkroids.com community thread, Injectco, Peptide Initiative ⚠️.
Vendor product pages (commercial flag on every one): Pure Rawz, Limitless Peptides, Limitless BioChem EU, Maylips, Peptide Partners, Cosmic Peptides, Beyond Peptides, Peptide Works, Core Peptides, Verified Peptides, Nextech Labs, Pure Health Peptides, Peptide Sciences (now shut down).

Retrieval-limitations disclosure (substantive — preserved from Pass 2). Direct Reddit thread retrieval failed for r/Peptides, r/PeptideUmbrella, r/Biohackers, r/longevity, r/Nootropics, r/macular_degeneration, r/SteroidsHGH, r/AgingBiology, r/Cardiomyopathy threads concerning SS-31. The widely-cited “r/Peptides 2024 thread — you don’t feel SS-31 kick in like a stimulant” claim is sourced through Real Peptides’ aggregator and could not be confirmed at primary thread / permalink resolution. No Reddit permalinks have been fabricated; no vote counts or quoted upvoted-comment text are reported from threads that were not directly retrieved. The MESO-Rx “SS-31 raw powder vendor (price?)” thread is referenced from a related-threads sidebar; the body was not opened at per-post resolution. Vigorous Steve podcast/YouTube episodes are confirmed at title/metadata level (IMDb, Castbox, Podtail); audio/video bodies were not transcribed and specific dose figures Steve states in-episode are not quoted. The Peter Attia Drive SS-31 episode is confirmed via the Amazon Music chapter marker but the episode body was not directly listened to. AMD self-treatment threads on r/macular_degeneration could not be retrieved; AMD self-experimenter discussion is documented via BrightFocus and Ophthalmology Times secondary coverage. Telegram / Discord chemistry-group content was not indexed by standard web search. Pre-2020 EliteFitness / AnabolicMinds / ProMuscle threads from the Bendavia era could not be retrieved at thread resolution; the 2014–2018 community-discovery timeline is inferred from aggregator references and continuous-thread visibility of MOTS-c-anchored discussion. No archive.org snapshots were opened in this pass.

14. Audit / Refresh Trail

Composed: 15 May 2026
Science-layer source: ss-31_sci_2026-05-15_D08.md (Pass 1; refreshed 2026-05-15)
Community-layer source: ss-31_com_2026-05-15_C56.md (Pass 2; compiled 2026-05-15)
Section 4 Last regulatory review: 2026-05-15
Two-molecule calibration block status: Not applicable. SS-31, elamipretide, MTP-131, Bendavia (historical), and Forzinity (approved) all refer to the same H-D-Arg-Dmt-Lys-Phe-NH₂ tetrapeptide. Successor compound SBT-272 / bevemipretide is a different molecule but is not sold under “SS-31” in community channels and does not warrant the calibration treatment.
Next refresh triggers:
- NuPOWER (Phase 3 PMM, nDNA-restricted) peer-reviewed primary readout — the single largest evidence-base shift possible for the non-Barth indications.
- ReNEW (Phase 3 dry AMD) peer-reviewed primary readout (NCT06373731; 96 weeks; ongoing).
- FDA confirmatory trial commitment for accelerated approval — published study protocol or interim analysis would update Section 4.1.
- Any FDA action on a non-Barth indication (label expansion, additional approval, withdrawal of accelerated approval).
- WADA 2027 List update (effective 1 January 2027) — possible explicit listing in S4 or another category.
- Any published independent (non-Szeto-co-authored) replication of cardiolipin-binding biophysics.
- Any peer-reviewed analytical-quality survey of research-grade SS-31 (D-Arg vs L-Arg substitution incidence; HPLC characterisation of vendor product).
- Any peer-reviewed RCT of SS-31 in healthy aging, sarcopenia, or longevity endpoints — the single largest gap in the catalog for this compound.
- Material shifts in the grey-market vendor landscape (further vendor shutdowns, FDA enforcement actions, COA scandals).
- Resolution of the paradoxical-fatigue community signal — either by community convergence on a mechanism or by a regulated trial measuring it.
- First published WADA sanction involving elamipretide as a named substance.